Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

24 of 28+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• ALLCDC NCCDPHP · U48

  Optimal survey questions for prostate cancer screening and shared decision-making

  New York University School of Medicine· New York, United States· US$443,904 awarded in fiscal year 2025· until Sept 2029

• ALLCDC NCCDPHP · U48

  Developing and Evaluating Computable Phenotypes to Identify Active Surveillance in Prostate Cancer Using Electronic Health Record Data

  Univ of Massachusetts Med Sch Worcester· Worcester, United States· US$399,303 awarded in fiscal year 2025· until Sept 2028

• NIH NCI · R37

  Targeting Lactylation of Critical Drivers in Neuroendocrine Prostate Cancer for Therapy

  University of Kentucky· Lexington, United States· US$453,367 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R43

  De Novo Minibinder Radiotheranostics for Targeted Treatment of Prostate Cancer

  Vesto Therapeutics, Inc· Seattle, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R42

  Dual Acting Bone Defenders for Inhibiting Cancer Mediated Bone Destruction

  Bonestrong Therapeutics Inc.· Portland, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 919 running projects, newest first. Listed amounts together: US$580.4m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

  NCT05582031· Translational Research in Oncology· Updated 7 Jun 2023

  “Study never started/ will not proceed.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

  NCT04934722· Merck Sharp & Dohme LLC· Source

• Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT06866548· Shanghai Changzheng Hospital· Source

• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

  NCT02861573· Merck Sharp & Dohme LLC· Source

• Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

  NCT07090148· University of Wisconsin, Madison· Source

• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

  NCT03493945· National Cancer Institute (NCI)· Source

• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

  NCT04580485· Incyte Corporation· Source

• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Circulating inflammatory proteins mediate the causal relationship between blood alliin and cancer: A two-step, multivariable Mendelian randomization study.

  Medicine (Baltimore), Nov 2026

• Prioritizing context-specific genetic risk mechanisms in 11 solid cancers.

  J Natl Cancer Inst, Oct 2026

• Identification of immune cell type-specific susceptibility genes in multiple cancers using transcriptome-wide association studies.

  J Natl Cancer Inst, Sept 2026

• Spatial Genetic Mapping of Normal Human Prostate Tissue Identifies Epithelial Compartments Enriched for Prostate Cancer Association.

  Mol Carcinog, Aug 2026

• Genetic variation in oxidative stress and detoxification pathways associated with prostate cancer susceptibility: a pathway-based analysis.

  Free Radic Biol Med, Aug 2026

• Population-Specific Genetic Markers of Prostate Cancer Risk in Kazakh Men: Association Analysis of 102 SNPs and Risk Prediction Modeling.

  Genes (Basel), Aug 2026

• Polygenic Risk Score for Adult Idiopathic Hydrocele Testis: Susceptibility and Severity in a Japanese Cohort.

  Int J Mol Sci, Aug 2026

• Causal association and shared mechanisms between Graves' disease and prostate cancer: insights from Mendelian randomization, machine learning, and comprehensive bioinformatics.

  Aging Male, Jul 2026

• Within-sibling attenuation of polygenic risk score accuracy: investigating the effects of principal component analysis, LD score regression, and mixed model association in the UK Biobank.

  Hum Genet, Jul 2026

• The Multiethnic Cohort: A Resource for the Study of Genetic and Nongenetic Cancer Risk across Populations.

  Cancer Epidemiol Biomarkers Prev, Jul 2026

  Iona Cheng

See which targets of this disease your abstract mentions, and go to the people working on them.